$364 Million is the total value of Sands Capital Ventures, LLC's 19 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TXG | New | 10X Genomics, Inc. | $21,800,000 | – | 481,770 | +100.0% | 5.99% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UIPATH INC | 9 | Q3 2023 | 30.2% |
| DOORDASH INC | 9 | Q3 2023 | 19.6% |
| SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
| ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
| 908 DEVICES INC | 9 | Q3 2023 | 1.8% |
| TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
| TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
| CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
| SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
| ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-15 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-09 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.